Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
Daptomycin demonstrated in vitro (MIC(90), 4 μg/ml) and in vivo activities against Bacillus anthracis. Twice-daily treatment with a dose of 50 mg/kg of body weight was begun 24 h after challenge and continued for 14 or 21 days; results were compared to those for controls treated with phosphate-buffered saline or ciprofloxacin. Day 43 survival rates were 6/10 mice for the 14-day and 9/10 mice for the 21-day treatment groups, compared to survival with ciprofloxacin: 8/10 and 9/10 mice, respectively. Culture results from tissues removed at the termination of the experiment were negative.
Heine
Henry S
HS
Division of Bacteriology, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702-5011, USA. hheine@ordwayresearch.org
Bassett
Jennifer
J
Miller
Lynda
L
Purcell
Bret K
BK
Byrne
W Russell
WR
D000818:Animals; D000881:Anthrax / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001408:Bacillus anthracis / Q000187:drug effects* / Q000472:pathogenicity; D002939:Ciprofloxacin / Q000627:therapeutic use; D017576:Daptomycin / Q000627:therapeutic use*; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D013171:Spores, Bacterial / Q000187:drug effects* / Q000472:pathogenicity*
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D017576:Daptomycin